237 related articles for article (PubMed ID: 31682002)
1. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Eyre TA; Roeker LE; Fox CP; Gohill SH; Walewska R; Walter HS; Forconi F; Broom A; Arumainathan A; Brander DM; Allan JN; Schuster SJ; Hill BT; Lansigan F; Cheson BD; Lamanna N; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Pearson L; Pagel JM; Jacobs R; Mato AR
Br J Haematol; 2020 Mar; 188(6):918-923. PubMed ID: 31682002
[TBL] [Abstract][Full Text] [Related]
2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.
Wierda WG; Byrd JC; Davids MS; Furman RR; Cheson BD; Barr PM; Eradat H; Heffner L; Zhou L; Verdugo M; Potluri J; Choi M
Br J Haematol; 2019 Jun; 185(5):961-966. PubMed ID: 30478940
[No Abstract] [Full Text] [Related]
5. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
Eyre TA; Kirkwood AA; Gohill S; Follows G; Walewska R; Walter H; Cross M; Forconi F; Shah N; Chasty R; Hart A; Broom A; Marr H; Patten PEM; Dann A; Arumainathan A; Munir T; Shankara P; Bloor A; Johnston R; Orchard K; Schuh AH; Fox CP;
Br J Haematol; 2019 May; 185(4):656-669. PubMed ID: 30768675
[TBL] [Abstract][Full Text] [Related]
6. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
7. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Hillmen P; Rawstron AC; Brock K; Muñoz-Vicente S; Yates FJ; Bishop R; Boucher R; MacDonald D; Fegan C; McCaig A; Schuh A; Pettitt A; Gribben JG; Patten PEM; Devereux S; Bloor A; Fox CP; Forconi F; Munir T
J Clin Oncol; 2019 Oct; 37(30):2722-2729. PubMed ID: 31295041
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax: A new wave in hematooncology.
Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R
Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371
[TBL] [Abstract][Full Text] [Related]
10. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
13. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
Gribben JG
Br J Haematol; 2020 Mar; 188(6):844-851. PubMed ID: 31858596
[TBL] [Abstract][Full Text] [Related]
14. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
15. An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia.
Salvaris R; Opat S
Future Oncol; 2021 Feb; 17(4):371-387. PubMed ID: 33064021
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia.
Guru Murthy GS; Atallah E
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):346-350. PubMed ID: 37363977
[TBL] [Abstract][Full Text] [Related]
18. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
19. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
20. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]